US20240026286A1 - Method of producing cancer stem cells - Google Patents
Method of producing cancer stem cells Download PDFInfo
- Publication number
- US20240026286A1 US20240026286A1 US18/480,956 US202318480956A US2024026286A1 US 20240026286 A1 US20240026286 A1 US 20240026286A1 US 202318480956 A US202318480956 A US 202318480956A US 2024026286 A1 US2024026286 A1 US 2024026286A1
- Authority
- US
- United States
- Prior art keywords
- gel
- cells
- cancer
- stem cells
- cell population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 176
- 201000011510 cancer Diseases 0.000 title claims abstract description 165
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 126
- 238000000034 method Methods 0.000 title claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 241
- 239000000126 substance Substances 0.000 claims abstract description 72
- 238000012258 culturing Methods 0.000 claims abstract description 62
- 102000004264 Osteopontin Human genes 0.000 claims abstract description 50
- 108010081689 Osteopontin Proteins 0.000 claims abstract description 50
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 33
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- -1 poly(sodium p-styrene sulfonate) Polymers 0.000 claims description 40
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 23
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 19
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 18
- 239000004793 Polystyrene Substances 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 229920001798 poly[2-(acrylamido)-2-methyl-1-propanesulfonic acid] polymer Polymers 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- WFKDPJRCBCBQNT-UHFFFAOYSA-N n,2-dimethylprop-2-enamide Chemical compound CNC(=O)C(C)=C WFKDPJRCBCBQNT-UHFFFAOYSA-N 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims 2
- 229920002939 poly(N,N-dimethylacrylamides) Polymers 0.000 abstract description 28
- 239000000463 material Substances 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 282
- 230000006698 induction Effects 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 24
- 238000011529 RT qPCR Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000002771 cell marker Substances 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 12
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 230000004655 Hippo pathway Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003505 polymerization initiator Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- XFTALRAZSCGSKN-UHFFFAOYSA-M sodium;4-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=C(C=C)C=C1 XFTALRAZSCGSKN-UHFFFAOYSA-M 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- WYFUZXBQKVIPQF-UHFFFAOYSA-N (prop-2-enoylamino)methyl propane-1-sulfonate;sodium Chemical compound [Na].CCCS(=O)(=O)OCNC(=O)C=C WYFUZXBQKVIPQF-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100040557 Osteopontin Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010017222 Cyclin-Dependent Kinase Inhibitor p57 Proteins 0.000 description 2
- 102000004480 Cyclin-Dependent Kinase Inhibitor p57 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 2
- HSOOIVBINKDISP-UHFFFAOYSA-N 1-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(CCC)OC(=O)C(C)=C HSOOIVBINKDISP-UHFFFAOYSA-N 0.000 description 1
- BJELTSYBAHKXRW-UHFFFAOYSA-N 2,4,6-triallyloxy-1,3,5-triazine Chemical compound C=CCOC1=NC(OCC=C)=NC(OCC=C)=N1 BJELTSYBAHKXRW-UHFFFAOYSA-N 0.000 description 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 description 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- TURITJIWSQEMDB-UHFFFAOYSA-N 2-methyl-n-[(2-methylprop-2-enoylamino)methyl]prop-2-enamide Chemical compound CC(=C)C(=O)NCNC(=O)C(C)=C TURITJIWSQEMDB-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BXAAQNFGSQKPDZ-UHFFFAOYSA-N 3-[1,2,2-tris(prop-2-enoxy)ethoxy]prop-1-ene Chemical compound C=CCOC(OCC=C)C(OCC=C)OCC=C BXAAQNFGSQKPDZ-UHFFFAOYSA-N 0.000 description 1
- UYRCWWINMMLRGJ-UHFFFAOYSA-N 3-ethenoxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC=C UYRCWWINMMLRGJ-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- JHWGFJBTMHEZME-UHFFFAOYSA-N 4-prop-2-enoyloxybutyl prop-2-enoate Chemical compound C=CC(=O)OCCCCOC(=O)C=C JHWGFJBTMHEZME-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000997670 Homo sapiens Integrin beta-8 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000626163 Homo sapiens Tenascin-X Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100033336 Integrin beta-8 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100024549 Tenascin-X Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 1
- VHSPRUFVQLFKKA-UHFFFAOYSA-N [Cl-].CC=CC(=O)NCCC[N+](C)(C)C Chemical compound [Cl-].CC=CC(=O)NCCC[N+](C)(C)C VHSPRUFVQLFKKA-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ZPOLOEWJWXZUSP-WAYWQWQTSA-N bis(prop-2-enyl) (z)-but-2-enedioate Chemical compound C=CCOC(=O)\C=C/C(=O)OCC=C ZPOLOEWJWXZUSP-WAYWQWQTSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical compound C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IQIJRJNHZYUQSD-UHFFFAOYSA-N ethenyl(phenyl)diazene Chemical compound C=CN=NC1=CC=CC=C1 IQIJRJNHZYUQSD-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- VPYJNCGUESNPMV-UHFFFAOYSA-N triallylamine Chemical compound C=CCN(CC=C)CC=C VPYJNCGUESNPMV-UHFFFAOYSA-N 0.000 description 1
- UZNHKBFIBYXPDV-UHFFFAOYSA-N trimethyl-[3-(2-methylprop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)NCCC[N+](C)(C)C UZNHKBFIBYXPDV-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 101150020580 yap1 gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
Definitions
- the present invention relates to a method of producing cancer stem cells.
- Cancer stem cells are defined as cells having both a self-replicating ability and pluripotency, and it has been recently revealed that the cancer stem cell exhibits treatment resistance to radiation therapy, chemotherapy and molecular targeted therapy, and is a cause of cancer relapse and metastasis. Since usually only an extremely small number of cancer stem cells are present in a tumor, it has been difficult to reveal and research the properties of cancer stem cells despite the importance thereof. Thus, in order to develop a definitive treatment targeted at cancer stem cells by elucidating the mechanism behind cancer relapse and metastasis as well as treatment resistance, it is extremely important to increase the ratio of cancer stem cells present among cancer cells and establish methods for the isolation and concentration thereof.
- an object of the present invention is to provide a means and method enabling the preparation of cancer stem cells without requiring expensive equipment, at comparatively inexpensive culturing costs, and in a comparatively short period of time, and to provide a means and method for such preparation of cancer stem cells.
- the inventors of the present invention attempted a completely different approach from that of the prior art in order to provide a means and method for preparing cancer stem cells. Namely, the inventors of the present invention examined the culturing of cancer cells including human cancer stem cells using a synthetic polymer gel developed and produced by Jian Ping Gong, one of the present inventors (PTL 1). As a result, the inventors of the present invention found that, as a result of using a portion of that synthetic polymer gel, cancer stem cells included in cancer cells are cultured preferentially in comparison with other cancer cells and cancer cells can be obtained that have an increased concentration of cancer stem cells, thereby leading to completion of the present invention.
- the present invention is as described below.
- a method of producing cancer stem cells comprising:
- the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- a method for testing the strength of the tendency for cancer cells to convert to cancer stem cells comprising:
- a method of testing an effect of a test substance on cancer stem cells comprising:
- the living cell population containing cancer stem cells is a living cell population obtained by culturing a living cell population containing cancer cells in the presence of the gel substance.
- the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- An agent for inducing conversion of cancer cells to cancer stem cells containing a gel substance that induces expression of osteopontin in at least a portion of cells contained in a living cell population.
- a kit for inducing conversion of cancer cells to cancer stem cells comprising the following (1) and (2):
- the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- cancer cells having an increased concentration of cancer stem cells can be obtained by culturing cancer cells using a specific synthetic polymer gel as a scaffold.
- ordinary culture medium such as DMEM containing 10% fetal bovine serum
- expression of stem cell marker molecules can be induced in a short period of time such as one day.
- cancer cells having an increased concentration of cancer stem cells can be prepared from cancer cells collected from a cancer patient, and by using these cancer cells having an increased concentration of cancer stem cells, the properties of stem cells during relapse can be predicted at the time of the initial cancer diagnosis, for example. Moreover, this enables a diagnosis to be made for administering a therapeutic drug for preventing relapse. In addition, the characteristics of cancer stem cells and applicable therapeutic drugs can be predicted in the case of having relapsed prior to a cancer patient receiving molecular targeted therapy.
- the present invention can serve as the foundation for the development of novel testing methods for selecting cancer treatment drugs.
- FIG. 1 indicates photographs of cells of a glioblastoma cell line (U138) on DN gel after 16 hours, 3 days and 6 days in Example 1(1).
- FIG. 2 indicates photographs of a glioblastoma cell line (KMG4) and oligodendrocytes after culturing for 8 days along with photographs of cells of glioblastoma cell lines (U138, U343) after culturing for 21 days (sphere formation) in Example 1(1) (PS: polystyrene culture dish, DN: DN gel).
- FIG. 3 indicates photographs of primary cells of glioblastoma cell lines (G137, G140, G144, G150) after culturing for 24 hours on DN gel (sphere formation) in Example 1(1).
- FIG. 4 indicates photographs of cells of brain tumor cell lines KMG4, G137, G140, G144 and G150 after culturing for 24 hours and 48 hours in Example 1(1).
- FIG. 5 indicates the results of confirming induction of expression of Sox2, Nanog and Oct3/4 mRNAs by qRT-PCR after culturing KMG4, U138 and U343 for 3 days in Example 1(1).
- FIG. 6 indicates the results of confirming induction of expression of Sox2 protein in sphere-formed KMG4 on DN gel in Example 1(1).
- FIG. 7 indicates the results of confirming induction of expression of Sox2, Nanog and Oct3/4 mRNAs by qRT-PCR for brain tumor cell lines G137, G140, G144, G150 and G145 in Example 1(1).
- FIG. 8 A indicates photographs of cells after culturing a lung cancer cell line (H209) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 1(1).
- FIG. 8 B indicates photographs of cells after culturing a lung cancer cell line (SBC3) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 1(1).
- FIG. 9 A indicates photographs of cells after culturing an ovarian cancer cell line (KF28) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR (PS3 to PS7, NC3 to NC7 and DN3 to DN7 from left to right) in Example 1(1).
- stem cell markers Sox2, Nanog, Oct3/4 mRNAs
- FIG. 9 B indicates photographs of cells after culturing an ovarian cancer cell line (Tu-OM-1) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR (PS3 to PS7, NC3 to NC7 and DN3 to DN7 from left to right) in Example 1(1).
- stem cell markers Sox2, Nanog, Oct3/4 mRNAs
- FIG. 10 indicates the results of microarray analyses (following extraction of total RNA from KMG4 cells cultured for 6, 24 and 48 hours and conversion to cDNA) in Example 1(2).
- FIG. 11 indicates the results of microarray analyses (following extraction of total RNA from KMG4 cells cultured for 6, 24 and 48 hours and conversion to cDNA) in Example 1(2).
- FIG. 12 is a schema of the mechanism behind induction of cancer stemness from cancer cells.
- FIG. 13 indicates the results of analyzing tumor-forming ability in vivo in mice in Example 1(3).
- FIG. 14 indicates the results of analyzing tumor-forming ability in vivo in mice in Example 1(3).
- FIG. 15 indicates photographs of brain tumor cell line KMG4 cells on DN gel, PCDME gel and PNaSS gel in Example 2(1).
- FIG. 16 indicates the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 2(1).
- FIG. 17 indicates the results of analyzing tumor-forming ability in vivo in mice by synthetic polymer gel-induced brain tumor stem cells in Example 2(2).
- FIG. 18 indicates the results of testing conversion of cancer patient-derived primary cultured cells to stem cells by polymer gel in Example 3.
- the photographs indicate the expression levels of EGFR and PDGFR in G144 cells cultured on a PS dish and DN gel.
- FIG. 19 indicates the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR in Example 2(1).
- FIG. 20 indicates the results of confirming induction of expression of osteopontin (OPN) mRNA in KMG 4 cells cultured on four types of polymer gels (PA, PAMPS, PDMA and PAAc gel) by qRT-PCR along with the results in cells cultured in DN, PCDME and PNaSS gels in Example 4.
- OPN osteopontin
- FIG. 21 indicates the results of confirming induction of expression of stem cell marker molecules (Oct3/4, Nanog mRNAs) in KMG4 cells cultured on four types of polymer gels (PA, PAMPS, PDMA and PAAc gels) by qRT-PCR along with the results in cells cultured in DN, PCDME and PNaSS gels in Example 4.
- stem cell marker molecules Oct3/4, Nanog mRNAs
- FIG. 22 indicates photographs of brain tumor KMG4 cells on four types of polymer gels (PA, PAMPS, PDMA and PAAc gels) along with photographs of the cells cultured on DN, PCDME and PNaSS gels in Example 4.
- PA polymer gels
- a first aspect of the present invention relates to a method of producing cancer stem cells.
- This production method comprises obtaining a living cell population containing cancer stem cells by culturing a living cell population containing cancer cells in the presence of a gel substance.
- the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population.
- a living cell population containing cancer cells is used as a starting material, this cell population is cultured in the presence of a gel substance, and a living cell population containing cancer stem cells is obtained as the resulting culture.
- the living cell population containing cancer cells used as a starting material can be, for example, a specimen (tissue section) from a body containing cancer cells collected from a cancer patient and primary cultured cancer cells.
- the culture medium and culture conditions are the same as those of culturing conventionally used to culture cancer cells with the exception of culturing in the presence of a gel substance.
- ordinary culture medium such as DMEM containing 10% fetal bovine serum
- culturing can be carried out by, for example, seeding the cells at a cell density of 1 ⁇ 10 5 /mL for 24 hours at 37° C. in a 5% CO 2 environment.
- Culturing can be carried out in a state in which the cells are able to contact the surface of the gel substance, and more specifically, can be carried out on a sheet-like gel substance.
- culturing is not limited to that carried out on a sheet-like gel substance, but rather any method can be used provided culturing is carried out in a state in which the cells are able to contact with the surface of the gel substance.
- a particulate gel substance can be used and culturing can be carried out while allowing a culture medium having the particulate gel substance dispersed therein to stand undisturbed or while stirring.
- the above-mentioned gel substance is selected from materials that induce expression of osteopontin in at least a portion of the cells contained in the living cell population.
- a gel substance can be, for example, a synthetic polymer gel composed of double network gel (DN gel), PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- DN gel double network gel
- PNaSS gel PNaSS gel
- PCDME gel PA gel
- PAMPS gel PDMA gel
- PAAc gel PAAc gel
- induction of expression of a brain tumor stem cell marker in cells obtained by culturing a living cell population containing cancer cells that have been cultured on a synthetic polymer gel in the present invention was determined to be caused by induction of the expression of osteopontin in cells cultured on the synthetic polymer gel.
- Cancer cells have receptors for osteopontin such as CD44 or integrin (ITG) on the surface thereof, and the Hippo pathway has been determined to be activated from the osteopontin/CD44 signal pathway while cell adhesion molecules including FAK and various types of kinase groups including Src, Akt, ERK and p38MAPK have been determined to be activated from the osteopontin/ITG pathway (NPL 7).
- osteopontin for which expression has been induced was indicated as activating the Hippo pathway and various kinase groups via osteopontin receptors on the surface of cancer cells and accelerating the expression of Oct3/4, Sox2 and Nanog, while expression of stem cell markers was determined to be suppressed downstream from the Hippo pathway in brain tumor cells.
- a TAZ transcriptional coactivator
- NPL 8 cancer stemness
- YAP/TAZ mechanical stimulation
- NPL 9 and NPL 10 a sensor of mechanical stimulation
- the above-mentioned gel substance is selected from materials that induce expression of osteopontin in at least a portion of the cells contained in a living cell population.
- gel substances having such a property include synthetic polymer gels composed of double network gel (DN gel), PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel and PAAc gel.
- DN gel double network gel
- PNaSS gel PNaSS gel
- PCDME gel PA gel
- PAMPS gel PDMA gel
- PAAc gel PAAc gel
- whether or not the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population can be determined by confirming induction of the expression of osteopontin (OPN) mRNA in any one type of cell contained in the above-mentioned living cell population by qRT-PCR.
- OPN osteopontin
- DN gel double network gel
- Examples of double network gel include the following two types of gels.
- a double network gel is the gel described in PTL 1, and a specific example thereof is a gel having an interpenetrating network structure composed of PAMPS (poly(AMPS)) as the first network structure (A) and PDMA as the second network structure (B) formed within the first network structure (A).
- PAMPS poly(AMPS)
- PAMPS poly(2-acrylamido-2-methyl-1-propanesulfonic acid)
- PDMA is the abbreviation for poly(N,N-dimethylacrylamide).
- NPL 11 can be referred to regarding double network gel.
- PNaSS gel is a gel composed of poly(sodium p-styrene sulfonate) (PNaSS) and examples thereof are described in PTL 2, NPL 13 and NPL 14. More specifically, PNaSS gel can be prepared by polymerizing sodium p-styrene sulfonate with a crosslinking agent. Examples of crosslinking agents include compounds similar to crosslinking agents able to be used with PCDME gel to be subsequently described such as methylenebisacrylamide.
- PCDME gel is a gel that contains poly-N-(carboxymethyl)-N,N-dimethyl-2-(methacryloyloxy) ethanaminium (PCDME), and an example thereof is described in PTL 3. More specifically, PCDME is a gel compound that contains PCDME as the main chain thereof in which this main chain is crosslinked with a crosslinking agent. PCDME can be prepared by polymerizing a carboxymethylbetaine monomer, which is a monomer component of PCDME, with a crosslinking agent.
- At least one crosslinking agent is selected from the group consisting of, for example, methylenebisacrylamide, methylenebismethacrylamide, butanediol diacrylate, butanediol dimethacrylate, ethylene glycol diacrylate, ethylene glycol dimethacrylate, allyl (meth)acrylate, triallyl cyanurate, diallyl maleate, polyallyl ester, tetraallyloxyethane, triallylamine, tetraallyl ethylenediamine, pentaerythritol triallyl ester and ethylenebisacrylamide.
- PA gel is the abbreviation for polyampholyte gel and is a polymer having both acidic and basic functional groups.
- An example of the acidic group is sulfonic acid, while an example of the basic group is an ammonium group (aminium group).
- This polymer can be synthesized by using a monomer having sulfonic acid group or a salt thereof (such as styrene sulfonic acid, vinyl sulfonic acid, 2-acrylamido-2-methylpropane sulfonic acid, ethylene sulfonic acid, 2-methacryloxyethane-1-sulfonic acid, 3-methacryloxyethane-1-sulfonic acid, 3-(vinyloxy)propane-1-sulfonic acid or derivatives thereof) and a monomer having an ammonium group (aminium group) (such as diallyl dimethyl ammonium, 2-butyl-methacryloxyethyl trimethyl ammonium, 4-vinylbenzotrimethyl ammonium, butyl acrylate methacryloxyethyl trimethyl ammonium,or derivatives thereof) followed by copolymerizing these monomers. Examples thereof are described in NPL 16 and NPL 17.
- sodium p-styrene sulfonate and [3-(methacryloylamino)propyl]trimethylaminiumchloride were used to synthesize a copolymer gel by using oxoglutaric acid as a polymerization initiator.
- This gel is referred to as PA gel in the examples.
- PAMPS gel is a gel composed of poly(2-acrylamido-2-methyl-1-propanesulfonic acid). It is also an example of a constituent polymer of the above-mentioned double network gel.
- PAMPS gel is a copolymer gel synthesized by using sodium acrylamidomethylpropane sulfonate and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. Examples thereof are described in NPL 12 to NPL 15.
- PDMA gel is a gel composed of poly(N,N′-dimethylacrylamide).
- PDMA gel is a copolymer gel synthesized by using dimethylacrylamide and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. An example thereof is described in NPL 15.
- PAAc gel is a gel composed of poly(acrylic acid).
- PAAc gel is a copolymer gel synthesized by using acrylic acid and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. Examples thereof are described in NPL 12 and NPL 13.
- a living cell population containing cancer stem cells can be obtained as a culture without the use of special means with the exception of culturing in the presence of the gel substance.
- the cells contained in the living cell population are cancer stem cells can be determined according to, for example, the morphology of the cells or the expression level of Oct3/4, Sox2 and/or Nanog.
- cancer stem cells can be cells that exhibit, for example, a spherical structure.
- cells may be cancer stem cells despite not exhibiting a spherical structure (see Example 2).
- cells demonstrated increased expression levels of one or two or more of any of Oct3/4, Sox2 and/or Nanog can also be selected as cancer stem cells.
- Cancer cells in addition to cancer stem cells may be contained in the living cell population containing cancer stem cells as a culture.
- a second aspect of the present invention is a method for testing the strength of the tendency for cancer cells to convert to cancer stem cells.
- This method comprises culturing a living cell population containing cancer cells in the presence of a gel substance and measuring the quality and/or quantity of cancer stem cells present in the resulting culture medium.
- the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the above-mentioned living cell population, and is the same material as the material explained in the previously described first aspect.
- a living cell population containing cancer cells is cultured in the presence of a gel substance.
- the living cell population containing cancer cells can be at least a portion of collected tissue that contains cancer.
- the gel substance may be in the form of a sheet or particles.
- the culture method and culture conditions during culturing in the presence of the gel substance are basically the same as those explained in the first aspect.
- the quality and/or quantity of cancer stem cells in the resulting culture medium are measured. Measurement of the quality and/or quantity of cancer stem cells can be carried out by, for example, observing the appearance of cancer stem cells in the culture medium (observing for the presence of spherical cells or counting the number of spherical cells) or measuring the expression levels of one or two or more of any of Oct3/4, Sox2 and/or Nanog in the cancer stem cells present in the culture medium.
- the strength of the tendency for cancer cells to convert to cancer stem cells can be determined from the results obtained.
- the potential for relapse of collected tissue containing cancer can be diagnosed by medical professionals based on this result.
- a third aspect of the present invention relates to a method for testing the effect of a test substance on cancer stem cells.
- This method comprises culturing a living cell population containing cancer cells and/or cancer stem cells in the presence of a test substance and a gel substance.
- the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the above-mentioned living cell population, and is the same material as that explained in the previously described first aspect.
- the third aspect (method) of the present invention makes it possible to evaluate, for example, the effect of a test substance on cancer stem cells such as the suppression or promotion of growth of cancer stem cells, and as a result thereof, drugs can be screened that are able to suppress the growth of cancer stem cells.
- the gel substance may be in the form of a sheet or particles.
- the culture method and culture conditions during culturing in the presence of the gel substance are basically the same as those explained in the first aspect with the exception of the presence or absence of the test substance.
- culturing can be carried out in vivo or in vitro.
- a test substance having an effect on the growth of cancer stem cells can be easily screened by carrying out culturing in vitro.
- an effect of a test substance in the body on cancer stem cells can be determined more directly by testing in vivo.
- the living cell population containing cancer stem cells used in the third aspect (method) of the present invention is a living cell population obtained by, for example, culturing a living cell population containing cancer cells in the presence of a gel substance in the method of the first aspect.
- a fourth aspect of the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that contains a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population.
- the gel substance that induces expression of osteopontin in at least a portion of the cells contained in the living cell population is able to induce conversion of cancer cells to cancer stem cells as a result thereof. Therefore, the present invention provides an agent containing this gel substance that can be used to induce conversion of cancer cells to cancer stem cells.
- the gel substance can be a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- the gel substance used as an agent for inducing conversion of cancer cells to cancer stem cells can be in the form of, for example, a sheet or particles, the form is not intended to be limited thereto.
- the gel substance may be of any form provided it is a form that is suitable for inducing conversion of cancer cells to cancer stem cells.
- a fifth aspect of the present invention relates to a kit for inducing conversion of cancer cells to cancer stem cells that contains the following (1) and (2):
- the gel substance as (1) is a material that induces expression of osteopontin in at least a portion of the cells contained in a living cell population and is the same as that explained in the first and fourth aspects.
- the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- the culture medium for culturing cancer cells as (2) can be a culture medium typically used to culture a living cell population containing cancer cells, which is the object of culturing, or a culture medium suitable for culturing a living cell population containing cancer cells.
- Human glioblastoma cell lines (KMG4, U138, U343), human primary glioblastoma cells (G137, G140, G144, G150), lung cancer cell lines (H209, SBC3) and ovarian cancer cell lines (KF28, Tu-OM-1) were seeded on synthetic polymer DN gel at 1 ⁇ 10 5 /mL followed by culturing.
- Photographs of U138 cells after 16 hours, 3 days and 6 days are shown in FIG. 1 .
- photographs of KMG4 and oligodendrocyte cells after culturing for 8 days photographs of U138 and U343 cells after culturing for 21 days
- photographs of G137, G140, G144 and G150 cells after culturing for 24 hours are shown in FIG. 2 and FIG. 3 , respectively.
- photographs of KMG4, G137, G140, G144 and G150 cells after 24 hours and 48 hours are shown in FIG. 4.
- FIG. 8 A and FIG. 8 B indicate photographs of cells following culturing lung cancer cell lines (H209, SBC3) and the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR.
- FIG. 9 A and FIG. 9 B indicate photographs of cells following culturing of ovarian cancer cell lines (KF28, Tu-OM-1) and the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR.
- a microarray analysis was carried out in order to elucidate the mechanism behind the induction of expression of stem cell markers in glioblastoma cell line KMG4 seeded on DN gel (SurePrint G3 Human GE 8x60K v2, Agilent Technologies). After extracting total RNA from KMG4 cells cultured on DN gel for 6, 24 and 48 hours and converting the total RNA to cDNA, the cDNA was subjected to microarray analysis. Cells cultured on a PS dish for 6, 24 and 48 hours were used as a negative control. The results are shown in FIG. 10 and FIG. 11 .
- CD44 and ITG exist as osteopontin receptors, and the Hippo pathway has been determined to be activated from the osteopontin/CD44 signal pathway, while cell adhesion molecules including FAK and various types of kinase groups including Src, Akt, ERK and p38MAPK have been determined to be activated from the osteopontin/ITG pathway (see, for example, NPL 7).
- molecule activation patterns were determined to be broadly classified into three patterns when KMG 4 cells are seeded on DN gel (see FIG. 12 ).
- activation is increased in proportion of the cells depending on the time adhered on the DN gel (pFAK), (ii) activation begins soon after seeding on DN gel and remains activated (pAKT, p-p38MAPK), and (iii) activation consists of two peaks occurring at 6 hours and 48 hours after seeding the cells on DN gel (p-c-Met, pEGFR, pSrc, pERK).
- pFAK time adhered on the DN gel
- activation begins soon after seeding on DN gel and remains activated
- pAKT p-p38MAPK
- activation consists of two peaks occurring at 6 hours and 48 hours after seeding the cells on DN gel (p-c-Met, pEGFR, pSrc, pERK).
- Yap1 an important factor of the Hippo pathway, is knocked down by the siRNA method (knock-down efficiency: 80%)
- expression of each of Oct3/4, Sox2 and Nanog was determined
- the following experiment was carried out in order to analyze the tumor-forming ability of cancer stem cells induced on DN gel in vivo in mice.
- the experiment method is as indicated below.
- mice were divided into the following four groups: 1) mixed inoculation of KMG4 cells cultured for 3 days on DN gel with crushed DN gel (diameter: 100 pm or less); 2) inoculation of cells after culturing for 3 days on DN gel; 3) inoculation of cells after culturing for 3 days on PS dish; and 4) inoculation of crushed DN gel only. 500 cells were inoculated in each group. The results are shown in FIG. 13 and FIG. 14 . Prominent tumor formation was observed in the system consisting of mixed inoculation of gels seeded on DN gel with crushed DN gel of group 1). This suggests that continuous stimulation from DN gel is required to induce stemness.
- FIG. 15 indicates photographs of cells cultured for 3 days.
- FIG. 16 the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR are shown in FIG. 16 .
- FIG. 19 the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR are shown in FIG. 19 .
- PPN osteopontin
- PNaSS and PCDME gels were suggested to have the potential to be able to irreversibly induce conversion of cancer cells to cancer stem cells both alone and in a short period of time.
- Analyses were further carried out using four types of synthetic polymer gels (PA, PAMPS, PDMA, PAAc).
- Human brain tumor cell line (KMG4) cells were seeded at 1 ⁇ 10 5 cells/mL on synthetic polymer gels consisting of PA, PAMPS, PDMA and PAAc and cultured for 3 days, and the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR are shown in FIG. 20 , while the results of confirming stem cell marker molecules (Oct3/4 and Nanog mRNAs) by qRT-PCR are shown in FIG. 21 .
- FIG. 21 also indicate the expression analysis results for each of DN, PCDME and PNaSS gels for comparison.
- Induction of expression of stem cell marker molecules (Oct3/4 and Nanog mRNAs) and osteopontin (OPN) mRNA was confirmed in KMG4 cells cultured on PA, PAMPS, PDMA and PAAc gels in addition to that on DN, PCDME and PNaSS gels.
- FIG. 22 KMG4 cells seeded on PA, PAMPS and PDMA gels and then cultured for 3 days formed spheres. Although KMG4 cells seeded and cultured in the same manner on PAAc gel adhered loosely to the gel, extension on the gel was not observed (adhesive, non-extending).
- FIG. 22 also indicates photographs of KMG4 cells seeded on DN, PCDME, and PNaSS gels and cultured for 3 days (DN: sphere formation, PCDME and PNaSS: adhesion and extension).
- the present invention is useful in tumor-related fields in which stem cells are involved.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method of producing cancer stem cells that comprises culturing a living cell population containing cancer cells in the presence of a gel substance to obtain a living cell population containing cancer stem cells, wherein the gel substance is a material that induces expression of osteopontin in at least a portion of cells contained in the living cell population. Moreover, the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that comprises a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population. The gel substance is a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel. The present invention provides means and a method that enable the preparation of cancer stem cells in a relatively short period of time and at a relatively low culturing cost without requiring expensive equipment.
Description
- The present application is a §371 of International Application No. PCT/JP2018/005884, Feb. 20, 2018, which claims priority from Japanese Patent Application No. 2017-28833 filed on 20 Feb. 2017. The entire disclosure of each of the aforesaid applications is incorporated by reference in the present application.
- The present invention relates to a method of producing cancer stem cells.
- Cancer stem cells are defined as cells having both a self-replicating ability and pluripotency, and it has been recently revealed that the cancer stem cell exhibits treatment resistance to radiation therapy, chemotherapy and molecular targeted therapy, and is a cause of cancer relapse and metastasis. Since usually only an extremely small number of cancer stem cells are present in a tumor, it has been difficult to reveal and research the properties of cancer stem cells despite the importance thereof. Thus, in order to develop a definitive treatment targeted at cancer stem cells by elucidating the mechanism behind cancer relapse and metastasis as well as treatment resistance, it is extremely important to increase the ratio of cancer stem cells present among cancer cells and establish methods for the isolation and concentration thereof.
- Methods have been developed in recent years for isolating and concentrating cancer stem cells.
-
- (1) Isolation by spheroid formation: Spherical cell masses (spheroids) are formed by culturing cells while suspending in a serum-free medium followed by concentrating cancer stem cells (NPL 1).
- (2) Isolation by side population fractionation: Based on data indicating that cancer stem cells are resistant to anticancer drugs, a DNA binding reagent is incorporated into the cells followed by isolating and acquiring a cell population having a potent ability to discharge that reagent by FACS (NPL 2).
- (3) Isolation using cancer stem cell surface marker: Antibody to molecules specifically expressed on the surface of cancer stem cells is used to isolate and acquire cells expressing these molecules (NPL 3). For example, examples of colon cancer stem cell surface markers include LGR5, CD133, CD44, EpCAM, CD166, ALDH, CD24, CD26 and CD29.
- (4) Isolation using glucose-free medium under hypoxic conditions: A cancer cell population containing cancer stem cells is cultured in medium that is substantially free of glucose under hypoxic conditions (NPL 4).
- (5) Conventional technology for concentrating cancer stem cells in brain tumors: A technique referred to as a neurosphere assay is used. In addition to molecules of various types of cell growth factors and cytokines, this technique uses an extremely expensive culture broth that contains fetal bovine serum that is excluded in ordinary sphere formation assays (NPL 5). In addition, a technique is also used that uses laminin to isolate normal neural stem cells (NPL 6).
-
-
- [PTL 1] Japanese Patent Application Laid-open No. 2010-174063
- [PTL 2] Japanese Patent Application Laid-open No. 2010-158180
- [PTL 3] Japanese Patent Application Laid-open No. 2016-83276
-
-
- [NPL 1] Science, 1992, 255, 1707-1710
- [NPL 2] J. Exp. Med., 1996, 183, 1797-1806
- [NPL 3] Oncotarget, 2010, 1, 387-395
- [NPL 4] Cell Death Differ., 2011, 18, 829-840
- [NPL 5] Proc. Natl. Acad. Sci. USA, 2000, 97, 15720-15725
- [NPL 6] BMC Neurosci., 2008, 9, 71
- [NPL 7] Stem Cells, 2015, 33, 1705-1718
- [NPL 8] Genes Dev., 2011, 25, 2594-2609
- [NPL 9] Nature, 2011, 474, 179-183
- [NPL 10] Nat. Rev. Mol. Cell Biol., 2012, 13, 591-600
- [NPL 11] Science, 344, 161-162, 2014
- [NPL 12] Acta Biomaterialia, 6 (2010), 494-501
- [NPL 13] Biomaterials, 26 (2005), 4588-4596
- [NPL 14] Biomaterials, 28 (2007), 1752-1760
- [NPL 15] J. Tissue Eng. Regen. Med., 2015, 9, 375-388
- [NPL 16] Nature Materials, 12(10), 932-937, 2013
- [NPL 17] Journal of Materials Chemistry B., 1(36), 4555-4562, 2013
- The descriptions of
PTL 1 to 3 and NPL 1 to 17 are incorporated herein in their entirety by reference. - All of the above-mentioned methods have the problems of requiring expensive equipment, having high culturing costs, and requiring one week or more for culturing.
- Therefore, an object of the present invention is to provide a means and method enabling the preparation of cancer stem cells without requiring expensive equipment, at comparatively inexpensive culturing costs, and in a comparatively short period of time, and to provide a means and method for such preparation of cancer stem cells.
- The inventors of the present invention attempted a completely different approach from that of the prior art in order to provide a means and method for preparing cancer stem cells. Namely, the inventors of the present invention examined the culturing of cancer cells including human cancer stem cells using a synthetic polymer gel developed and produced by Jian Ping Gong, one of the present inventors (PTL 1). As a result, the inventors of the present invention found that, as a result of using a portion of that synthetic polymer gel, cancer stem cells included in cancer cells are cultured preferentially in comparison with other cancer cells and cancer cells can be obtained that have an increased concentration of cancer stem cells, thereby leading to completion of the present invention. The present invention is as described below.
- [1] A method of producing cancer stem cells, comprising:
-
- culturing a living cell population containing cancer cells in the presence of a gel substance to obtain a living cell population containing cancer stem cells, wherein
- the gel substance is a material that induces expression of osteopontin in at least a portion of cells contained in the living cell population.
- [2] The production method according to [1], wherein the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- [3] The method according to [1], wherein the living cell population containing cancer stem cells contains cells exhibiting a spherical shape.
- [4] The method according to any one of [1] to [3], wherein cells in the living cell population containing cancer stem cells have a higher expression level of Oct3/4, Sox2 and/or Nanog than that prior to culturing in the presence of the gel substance.
- [5] A method for testing the strength of the tendency for cancer cells to convert to cancer stem cells, comprising:
-
- culturing a living cell population containing cancer cells in the presence of a gel substance, and
- measuring the quality and/or quantity of cancer stem cells in the resulting culture medium; wherein
- the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population.
- [6] The method according to [5], wherein the living cell population containing cancer cells is at least a portion of collected tissue containing cancer.
- [7] The method according to [5] or [6], wherein the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- [8] A method of testing an effect of a test substance on cancer stem cells, comprising:
-
- culturing a living cell population containing cancer cells and/or cancer stem cells in the presence of a test substance and a gel substance; wherein
- the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population.
- [9] The method according to [8], wherein the culturing is carried out in vivo or in vitro.
- [10] The method according to [8] or [9], wherein the living cell population containing cancer stem cells is a living cell population obtained by culturing a living cell population containing cancer cells in the presence of the gel substance.
- [11] The method according to any one of [8] to [10], wherein the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- [12] An agent for inducing conversion of cancer cells to cancer stem cells, containing a gel substance that induces expression of osteopontin in at least a portion of cells contained in a living cell population.
- [13] The agent for inducing conversion according to [12], wherein the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- [14] The agent for inducing conversion according to or [13], wherein the gel substance is in the form of a sheet or particles.
- [15] A kit for inducing conversion of cancer cells to cancer stem cells comprising the following (1) and (2):
-
- (1) a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population, and
- (2) a culture broth for culturing cancer cells.
- [16] The kit according to [15], wherein the gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- [17] The kit according to or [16], wherein the gel substance is in the form of a sheet or particles.
- According to the present invention, cancer cells having an increased concentration of cancer stem cells can be obtained by culturing cancer cells using a specific synthetic polymer gel as a scaffold. In the present invention, ordinary culture medium (such as DMEM containing 10% fetal bovine serum) is the only reagent required other than the synthetic polymer gel and special equipment is not required. Moreover, expression of stem cell marker molecules can be induced in a short period of time such as one day.
- Consequently, as a result of using the present invention, cancer cells having an increased concentration of cancer stem cells can be prepared from cancer cells collected from a cancer patient, and by using these cancer cells having an increased concentration of cancer stem cells, the properties of stem cells during relapse can be predicted at the time of the initial cancer diagnosis, for example. Moreover, this enables a diagnosis to be made for administering a therapeutic drug for preventing relapse. In addition, the characteristics of cancer stem cells and applicable therapeutic drugs can be predicted in the case of having relapsed prior to a cancer patient receiving molecular targeted therapy. The present invention can serve as the foundation for the development of novel testing methods for selecting cancer treatment drugs.
-
FIG. 1 indicates photographs of cells of a glioblastoma cell line (U138) on DN gel after 16 hours, 3 days and 6 days in Example 1(1). -
FIG. 2 indicates photographs of a glioblastoma cell line (KMG4) and oligodendrocytes after culturing for 8 days along with photographs of cells of glioblastoma cell lines (U138, U343) after culturing for 21 days (sphere formation) in Example 1(1) (PS: polystyrene culture dish, DN: DN gel). -
FIG. 3 indicates photographs of primary cells of glioblastoma cell lines (G137, G140, G144, G150) after culturing for 24 hours on DN gel (sphere formation) in Example 1(1). -
FIG. 4 indicates photographs of cells of brain tumor cell lines KMG4, G137, G140, G144 and G150 after culturing for 24 hours and 48 hours in Example 1(1). -
FIG. 5 indicates the results of confirming induction of expression of Sox2, Nanog and Oct3/4 mRNAs by qRT-PCR after culturing KMG4, U138 and U343 for 3 days in Example 1(1). -
FIG. 6 indicates the results of confirming induction of expression of Sox2 protein in sphere-formed KMG4 on DN gel in Example 1(1). -
FIG. 7 indicates the results of confirming induction of expression of Sox2, Nanog and Oct3/4 mRNAs by qRT-PCR for brain tumor cell lines G137, G140, G144, G150 and G145 in Example 1(1). -
FIG. 8A indicates photographs of cells after culturing a lung cancer cell line (H209) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 1(1). -
FIG. 8B indicates photographs of cells after culturing a lung cancer cell line (SBC3) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 1(1). -
FIG. 9A indicates photographs of cells after culturing an ovarian cancer cell line (KF28) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR (PS3 to PS7, NC3 to NC7 and DN3 to DN7 from left to right) in Example 1(1). -
FIG. 9B indicates photographs of cells after culturing an ovarian cancer cell line (Tu-OM-1) and the results of confirming induction of expression of stem cell markers (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR (PS3 to PS7, NC3 to NC7 and DN3 to DN7 from left to right) in Example 1(1). -
FIG. 10 indicates the results of microarray analyses (following extraction of total RNA from KMG4 cells cultured for 6, 24 and 48 hours and conversion to cDNA) in Example 1(2). -
FIG. 11 indicates the results of microarray analyses (following extraction of total RNA from KMG4 cells cultured for 6, 24 and 48 hours and conversion to cDNA) in Example 1(2). -
FIG. 12 is a schema of the mechanism behind induction of cancer stemness from cancer cells. -
FIG. 13 indicates the results of analyzing tumor-forming ability in vivo in mice in Example 1(3). -
FIG. 14 indicates the results of analyzing tumor-forming ability in vivo in mice in Example 1(3). -
FIG. 15 indicates photographs of brain tumor cell line KMG4 cells on DN gel, PCDME gel and PNaSS gel in Example 2(1). -
FIG. 16 indicates the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR in Example 2(1). -
FIG. 17 indicates the results of analyzing tumor-forming ability in vivo in mice by synthetic polymer gel-induced brain tumor stem cells in Example 2(2). -
FIG. 18 indicates the results of testing conversion of cancer patient-derived primary cultured cells to stem cells by polymer gel in Example 3. The photographs indicate the expression levels of EGFR and PDGFR in G144 cells cultured on a PS dish and DN gel. -
FIG. 19 indicates the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR in Example 2(1). -
FIG. 20 indicates the results of confirming induction of expression of osteopontin (OPN) mRNA in KMG4 cells cultured on four types of polymer gels (PA, PAMPS, PDMA and PAAc gel) by qRT-PCR along with the results in cells cultured in DN, PCDME and PNaSS gels in Example 4. -
FIG. 21 indicates the results of confirming induction of expression of stem cell marker molecules (Oct3/4, Nanog mRNAs) in KMG4 cells cultured on four types of polymer gels (PA, PAMPS, PDMA and PAAc gels) by qRT-PCR along with the results in cells cultured in DN, PCDME and PNaSS gels in Example 4. -
FIG. 22 indicates photographs of brain tumor KMG4 cells on four types of polymer gels (PA, PAMPS, PDMA and PAAc gels) along with photographs of the cells cultured on DN, PCDME and PNaSS gels in Example 4. - <Method for Producing Cancer Stem Cells>
- A first aspect of the present invention relates to a method of producing cancer stem cells.
- This production method comprises obtaining a living cell population containing cancer stem cells by culturing a living cell population containing cancer cells in the presence of a gel substance. Moreover, the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population.
- In the method of producing cancer stem cells of the present invention, a living cell population containing cancer cells is used as a starting material, this cell population is cultured in the presence of a gel substance, and a living cell population containing cancer stem cells is obtained as the resulting culture.
- The living cell population containing cancer cells used as a starting material can be, for example, a specimen (tissue section) from a body containing cancer cells collected from a cancer patient and primary cultured cancer cells.
- The culture medium and culture conditions are the same as those of culturing conventionally used to culture cancer cells with the exception of culturing in the presence of a gel substance. For example, ordinary culture medium (such as DMEM containing 10% fetal bovine serum) can be used as culture medium, and culturing can be carried out by, for example, seeding the cells at a cell density of 1×105/mL for 24 hours at 37° C. in a 5% CO2 environment. Culturing can be carried out in a state in which the cells are able to contact the surface of the gel substance, and more specifically, can be carried out on a sheet-like gel substance. However, culturing is not limited to that carried out on a sheet-like gel substance, but rather any method can be used provided culturing is carried out in a state in which the cells are able to contact with the surface of the gel substance. For example, a particulate gel substance can be used and culturing can be carried out while allowing a culture medium having the particulate gel substance dispersed therein to stand undisturbed or while stirring.
- In the present invention, the above-mentioned gel substance is selected from materials that induce expression of osteopontin in at least a portion of the cells contained in the living cell population. Such a gel substance can be, for example, a synthetic polymer gel composed of double network gel (DN gel), PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel. However, these examples are not intended to be limiting, but rather the gel substance can be any material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population.
- As described in detail in Example 1(2), induction of expression of a brain tumor stem cell marker in cells obtained by culturing a living cell population containing cancer cells that have been cultured on a synthetic polymer gel in the present invention was determined to be caused by induction of the expression of osteopontin in cells cultured on the synthetic polymer gel. Cancer cells have receptors for osteopontin such as CD44 or integrin (ITG) on the surface thereof, and the Hippo pathway has been determined to be activated from the osteopontin/CD44 signal pathway while cell adhesion molecules including FAK and various types of kinase groups including Src, Akt, ERK and p38MAPK have been determined to be activated from the osteopontin/ITG pathway (NPL 7). As shown in
FIG. 12 , osteopontin for which expression has been induced (first step) was indicated as activating the Hippo pathway and various kinase groups via osteopontin receptors on the surface of cancer cells and accelerating the expression of Oct3/4, Sox2 and Nanog, while expression of stem cell markers was determined to be suppressed downstream from the Hippo pathway in brain tumor cells. - Furthermore, in glioblastoma, a TAZ (transcriptional coactivator), which is a transducer of the Hippo pathway, is known to be important in the acquisition of cancer stemness (NPL 8), while YAP/TAZ has been reported to be important as a sensor of mechanical stimulation (mechanotransduction) (NPL 9 and NPL 10). On the basis thereof, by culturing a living cell population containing cancer cells in a state that enables contact with a specific synthetic polymer gel, the cancer cells are stimulated by the synthetic polymer gel, acquire cancer stemness, and the concentration of cancer stem cells in the living cell population is presumed to increase.
- In the present invention, the above-mentioned gel substance is selected from materials that induce expression of osteopontin in at least a portion of the cells contained in a living cell population. Examples of gel substances having such a property include synthetic polymer gels composed of double network gel (DN gel), PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel and PAAc gel. In these synthetic gels, as indicated by the results of Example 2(1) and Example 4, induction of expression of osteopontin (OPN) mRNA in KMG4 cells cultured on these synthetic gels was able to be confirmed by qRT-PCR. In the present invention, whether or not the gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the living cell population can be determined by confirming induction of the expression of osteopontin (OPN) mRNA in any one type of cell contained in the above-mentioned living cell population by qRT-PCR.
- Examples of double network gel (DN gel) include the following two types of gels.
-
- (i) Gel having an interpenetrating network structure composed of a first network structure (A) and a second network structure (B) formed within the first network structure (A).
- (ii) Gel having an interpenetrating network structure composed of a first network structure (A) and a polymer (B′) formed within the first network structure (A).
- An example of a double network gel is the gel described in
PTL 1, and a specific example thereof is a gel having an interpenetrating network structure composed of PAMPS (poly(AMPS)) as the first network structure (A) and PDMA as the second network structure (B) formed within the first network structure (A). Poly(AMPS) and PAMPS are abbreviations for poly(2-acrylamido-2-methyl-1-propanesulfonic acid), while PDMA is the abbreviation for poly(N,N-dimethylacrylamide). NPL 11 can be referred to regarding double network gel. - PNaSS gel is a gel composed of poly(sodium p-styrene sulfonate) (PNaSS) and examples thereof are described in
PTL 2,NPL 13 andNPL 14. More specifically, PNaSS gel can be prepared by polymerizing sodium p-styrene sulfonate with a crosslinking agent. Examples of crosslinking agents include compounds similar to crosslinking agents able to be used with PCDME gel to be subsequently described such as methylenebisacrylamide. - PCDME gel is a gel that contains poly-N-(carboxymethyl)-N,N-dimethyl-2-(methacryloyloxy) ethanaminium (PCDME), and an example thereof is described in
PTL 3. More specifically, PCDME is a gel compound that contains PCDME as the main chain thereof in which this main chain is crosslinked with a crosslinking agent. PCDME can be prepared by polymerizing a carboxymethylbetaine monomer, which is a monomer component of PCDME, with a crosslinking agent. At least one crosslinking agent is selected from the group consisting of, for example, methylenebisacrylamide, methylenebismethacrylamide, butanediol diacrylate, butanediol dimethacrylate, ethylene glycol diacrylate, ethylene glycol dimethacrylate, allyl (meth)acrylate, triallyl cyanurate, diallyl maleate, polyallyl ester, tetraallyloxyethane, triallylamine, tetraallyl ethylenediamine, pentaerythritol triallyl ester and ethylenebisacrylamide. - PA gel is the abbreviation for polyampholyte gel and is a polymer having both acidic and basic functional groups. An example of the acidic group is sulfonic acid, while an example of the basic group is an ammonium group (aminium group). This polymer can be synthesized by using a monomer having sulfonic acid group or a salt thereof (such as styrene sulfonic acid, vinyl sulfonic acid, 2-acrylamido-2-methylpropane sulfonic acid, ethylene sulfonic acid, 2-methacryloxyethane-1-sulfonic acid, 3-methacryloxyethane-1-sulfonic acid, 3-(vinyloxy)propane-1-sulfonic acid or derivatives thereof) and a monomer having an ammonium group (aminium group) (such as diallyl dimethyl ammonium, 2-butyl-methacryloxyethyl trimethyl ammonium, 4-vinylbenzotrimethyl ammonium, butyl acrylate methacryloxyethyl trimethyl ammonium,or derivatives thereof) followed by copolymerizing these monomers. Examples thereof are described in
NPL 16 andNPL 17. - In the examples, sodium p-styrene sulfonate and [3-(methacryloylamino)propyl]trimethylaminiumchloride were used to synthesize a copolymer gel by using oxoglutaric acid as a polymerization initiator. This gel is referred to as PA gel in the examples.
- PAMPS gel is a gel composed of poly(2-acrylamido-2-methyl-1-propanesulfonic acid). It is also an example of a constituent polymer of the above-mentioned double network gel. PAMPS gel is a copolymer gel synthesized by using sodium acrylamidomethylpropane sulfonate and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. Examples thereof are described in
NPL 12 toNPL 15. - PDMA gel is a gel composed of poly(N,N′-dimethylacrylamide). In the examples, PDMA gel is a copolymer gel synthesized by using dimethylacrylamide and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. An example thereof is described in
NPL 15. - PAAc gel is a gel composed of poly(acrylic acid). In the examples, PAAc gel is a copolymer gel synthesized by using acrylic acid and methylenebisacrylamide as monomers and using oxoglutaric acid as a polymerization initiator. Examples thereof are described in
NPL 12 andNPL 13. - In the method of the present invention, a living cell population containing cancer stem cells can be obtained as a culture without the use of special means with the exception of culturing in the presence of the gel substance. Whether or not the cells contained in the living cell population are cancer stem cells can be determined according to, for example, the morphology of the cells or the expression level of Oct3/4, Sox2 and/or Nanog. With respect to morphology, cancer stem cells can be cells that exhibit, for example, a spherical structure. However, there are cases in which cells may be cancer stem cells despite not exhibiting a spherical structure (see Example 2). In addition, cells demonstrated increased expression levels of one or two or more of any of Oct3/4, Sox2 and/or Nanog can also be selected as cancer stem cells.
- Cancer cells in addition to cancer stem cells may be contained in the living cell population containing cancer stem cells as a culture.
- <Method for Testing Strength of Tendency for Cancer Cells to Convert to Cancer Stem Cells>
- A second aspect of the present invention is a method for testing the strength of the tendency for cancer cells to convert to cancer stem cells. This method comprises culturing a living cell population containing cancer cells in the presence of a gel substance and measuring the quality and/or quantity of cancer stem cells present in the resulting culture medium. The gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the above-mentioned living cell population, and is the same material as the material explained in the previously described first aspect.
- In the second aspect (method) of the present invention, a living cell population containing cancer cells is cultured in the presence of a gel substance. The living cell population containing cancer cells can be at least a portion of collected tissue that contains cancer.
- As explained in the first aspect, the gel substance may be in the form of a sheet or particles. The culture method and culture conditions during culturing in the presence of the gel substance are basically the same as those explained in the first aspect.
- The quality and/or quantity of cancer stem cells in the resulting culture medium are measured. Measurement of the quality and/or quantity of cancer stem cells can be carried out by, for example, observing the appearance of cancer stem cells in the culture medium (observing for the presence of spherical cells or counting the number of spherical cells) or measuring the expression levels of one or two or more of any of Oct3/4, Sox2 and/or Nanog in the cancer stem cells present in the culture medium.
- The strength of the tendency for cancer cells to convert to cancer stem cells can be determined from the results obtained. The potential for relapse of collected tissue containing cancer can be diagnosed by medical professionals based on this result.
- <Method for Testing Effect of Test Substance on Cancer Stem Cells>
- A third aspect of the present invention relates to a method for testing the effect of a test substance on cancer stem cells. This method comprises culturing a living cell population containing cancer cells and/or cancer stem cells in the presence of a test substance and a gel substance. The gel substance is a material that induces expression of osteopontin in at least a portion of the cells contained in the above-mentioned living cell population, and is the same material as that explained in the previously described first aspect.
- The third aspect (method) of the present invention makes it possible to evaluate, for example, the effect of a test substance on cancer stem cells such as the suppression or promotion of growth of cancer stem cells, and as a result thereof, drugs can be screened that are able to suppress the growth of cancer stem cells.
- As explained in the first aspect, the gel substance may be in the form of a sheet or particles. The culture method and culture conditions during culturing in the presence of the gel substance are basically the same as those explained in the first aspect with the exception of the presence or absence of the test substance. In addition, culturing can be carried out in vivo or in vitro. A test substance having an effect on the growth of cancer stem cells can be easily screened by carrying out culturing in vitro. In addition, an effect of a test substance in the body on cancer stem cells can be determined more directly by testing in vivo.
- The living cell population containing cancer stem cells used in the third aspect (method) of the present invention is a living cell population obtained by, for example, culturing a living cell population containing cancer cells in the presence of a gel substance in the method of the first aspect.
- <Agent for Inducing Conversion of Cancer Cells to Cancer Stem Cells>
- A fourth aspect of the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that contains a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population.
- As previously described, the gel substance that induces expression of osteopontin in at least a portion of the cells contained in the living cell population is able to induce conversion of cancer cells to cancer stem cells as a result thereof. Therefore, the present invention provides an agent containing this gel substance that can be used to induce conversion of cancer cells to cancer stem cells.
- The gel substance can be a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel. Although the gel substance used as an agent for inducing conversion of cancer cells to cancer stem cells can be in the form of, for example, a sheet or particles, the form is not intended to be limited thereto. The gel substance may be of any form provided it is a form that is suitable for inducing conversion of cancer cells to cancer stem cells.
- <Kit for Inducing Conversion of Cancer Cells to Cancer Stem Cells>
- A fifth aspect of the present invention relates to a kit for inducing conversion of cancer cells to cancer stem cells that contains the following (1) and (2):
-
- (1) gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population, and
- (2) culture medium for culturing cancer cells.
- The gel substance as (1) is a material that induces expression of osteopontin in at least a portion of the cells contained in a living cell population and is the same as that explained in the first and fourth aspects. The gel substance is a synthetic polymer gel composed of double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel.
- The culture medium for culturing cancer cells as (2) can be a culture medium typically used to culture a living cell population containing cancer cells, which is the object of culturing, or a culture medium suitable for culturing a living cell population containing cancer cells.
- The following provides a more detailed explanation of the present invention based on examples thereof. However, the examples are only intended to be exemplary and the present invention is not limited thereto.
- The synthesis methods, initial elastic moduli and degrees of swelling of the synthetic polymer double network (DN) gel, PCDME gel, PNaSS gel, PA gel, PAMPS gel, PDMA gel and PAAc gel used in the examples are as indicated below.
-
- (1) DN gel: Gel obtained by polymerizing PAMPS (poly(AMPS): poly(2-acrylamido-2-methyl-1-propanesulfonic acid)) as the first network with PDMA (poly(N,N-dimethylacrylamide)) as the second network. 2.1 g of sodium acrylamidomethylpropanesulfonate, 0.062 g of methylenebisacrylamide and 0.015 g of oxoglutaric acid were dissolved with pure water to obtain 10 mL of an aqueous solution using a 10 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×0.5 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel having a first network. This gel was divided into four portions, and when placed in 500 mL of an aqueous solution containing 99 g of N,N′-dimethylacrylamide, 0.15 g of methylenebisacrylamide and 0.15 g of oxoglutaric acid, the aqueous solution was absorbed and the gel swelled to about 10 times the volume thereof. The swollen gel was placed between glass plates and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a second network. The gel having these two types of synthesized networks was placed in pure water, the pure water was replaced three times, and unreacted raw materials were removed to obtain DN gel. The initial elastic modulus of the DN gel was 0.435 MPa and the degree of swelling was 7.3 g/g.
- (2) PCDME: Poly-N-(carboxymethyl)-N,N-dimethyl-2-(methacryloyloxy) ethanaminium. 6.5 g of carboxymethylbetaine monomer, 0.19 g of methylenebisacrylamide and 0.0044 g of oxoglutaric acid were dissolved with pure water to obtain 30 mL of an aqueous solution using a 30 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×1 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel. The synthesized gel was placed in pure water, the pure water was replaced three times and unreacted raw materials were removed to obtain PCDME gel. The initial elastic modulus of the PCDME gel was 0.0507 MPa and the degree of swelling was 8.6 g/g.
- (3) PNaSS: Poly(sodium p-styrene sulfonate). 2.1 g of sodium p-styrene sulfonate, 0.062 g of methylenebisacrylamide and 0.0015 g of oxoglutaric acid were dissolved with pure water to obtain 10 mL of an aqueous solution using a 10 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×0.5 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel. The gel was placed in pure water, the pure water was replaced three times, and unreacted raw materials were removed to obtain PNaSS gel. The initial elastic modulus of the PNaSS gel was 0.0026 MPa and the degree of swelling was 306.8 g/g.
- (4) PA: Polyampholyte. 6.2 g of sodium p-styrene sulfonate, 6.0 g of [3-(methylacryloylamino)propyl]trimethylaminiumchloride and 0.0083 g of oxoglutaric acid were dissolved with pure water to obtain 10 mL of an aqueous solution using a 30 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×1 mm and irradiated with ultraviolet light for 10 hours in an argon atmosphere to synthesize a gel. This was placed in pure water, the pure water was replaced three times and unreacted raw materials were removed to obtain PA gel.
- (5) PAMPS: Poly(2-acrylamido-2-methyl-1-propanesulfonic acid). 2.1 g of sodium acrylamidomethylpropane sulfonate, 0.062 g of methylenebisacrylamide and 0.015 g of oxoglutaric acid were dissolved with pure water to obtain 10 mL of an aqueous solution using a 10 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×0.5 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel. The synthesized gel was placed in pure water, the pure water was replaced three times and unreacted raw materials were removed to obtain PAMPS gel.
- (6) PDMA: Poly(N,N′-dimethylacrylamide). 3.3 g of dimethylacrylamide, 0.19 g of methylenebisacrylamide and 0.044 g of oxoglutaric acid were dissolved with pure water to obtain 30 mL of an aqueous solution using a 30 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×1 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel. The synthesized gel was placed in pure water, the pure water was replaced three times and unreacted raw materials were removed to obtain PDMA gel.
- (7) PAAc: Poly(acrylic acid). 2.2 g of acrylic acid, 0.19 g of methylenebisacrylamide and 0.044 g of oxoglutaric acid were dissolved with pure water to obtain 30 mL of an aqueous solution using a 30 mL volumetric flask. This was poured into a glass mold measuring 8 cm×8 cm×1 mm and irradiated with ultraviolet light for 8 hours in an argon atmosphere to synthesize a gel. The synthesized gel was placed in pure water, the pure water was replaced three times and unreacted raw materials were removed to obtain PAAc gel.
- Human glioblastoma cell lines (KMG4, U138, U343), human primary glioblastoma cells (G137, G140, G144, G150), lung cancer cell lines (H209, SBC3) and ovarian cancer cell lines (KF28, Tu-OM-1) were seeded on synthetic polymer DN gel at 1×105 /mL followed by culturing.
- Photographs of U138 cells after 16 hours, 3 days and 6 days are shown in
FIG. 1 . Moreover, photographs of KMG4 and oligodendrocyte cells after culturing for 8 days, photographs of U138 and U343 cells after culturing for 21 days, and photographs of G137, G140, G144 and G150 cells after culturing for 24 hours are shown inFIG. 2 andFIG. 3 , respectively. Moreover, photographs of KMG4, G137, G140, G144 and G150 cells after 24 hours and 48 hours are shown in FIG. 4. - After culturing KMG4, U138 and U343 for 3 days, induction of the expression of typical stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) was examined by qRT-PCR. Cells cultured in an ordinary polystyrene dish (PS dish) were used as a negative control. The results are shown in FIG. 5. Prominent induction of expression of the stem cell marker molecules on the DN gel was confirmed in comparison with cells cultured in the PS dish for each of the cells. In addition, induction of the expression of Sox2 protein was confirmed in sphere-formed KMG4 on the DN gel (
FIG. 6 ). The results of confirming induction of expression of typical stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR for G137, G140, G144, G150 and G145 are shown inFIG. 7 . -
FIG. 8A andFIG. 8B indicate photographs of cells following culturing lung cancer cell lines (H209, SBC3) and the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR.FIG. 9A andFIG. 9B indicate photographs of cells following culturing of ovarian cancer cell lines (KF28, Tu-OM-1) and the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR. - Elucidation of Mechanism behind Induction of Expression of Brain Tumor Stem Cell Markers on Synthetic Polymer DN Gel
- A microarray analysis was carried out in order to elucidate the mechanism behind the induction of expression of stem cell markers in glioblastoma cell line KMG4 seeded on DN gel (SurePrint G3 Human GE 8x60K v2, Agilent Technologies). After extracting total RNA from KMG4 cells cultured on DN gel for 6, 24 and 48 hours and converting the total RNA to cDNA, the cDNA was subjected to microarray analysis. Cells cultured on a PS dish for 6, 24 and 48 hours were used as a negative control. The results are shown in
FIG. 10 andFIG. 11 . - Eleven types of genes were identified for which expression increased by three-fold or more on DN gel in comparison with culturing on the PS dish at each of 6, 24 and 48 hours among the pathways for which expression fluctuated significantly on DN gel (osteoprotegerin, IL6, TNF, COL3A1, ITGB8, TNXB, VEGFA, osteopontin (SPP1), CDKN1C and TIMP3). Among them, those molecules for which increased expression was reconfirmed by qRT-PCR consisted of osteopontin and CDKN1C, and the gene that demonstrated the highest expression induction rate was osteopontin (SPP1). Expression of stem cell marker molecules decreased in cells in which osteopontin (SPP1) were knocked down by transfection with siRNA and cells treated with osteopontin neutralizing antibody in a confirmation experiment.
- CD44 and ITG exist as osteopontin receptors, and the Hippo pathway has been determined to be activated from the osteopontin/CD44 signal pathway, while cell adhesion molecules including FAK and various types of kinase groups including Src, Akt, ERK and p38MAPK have been determined to be activated from the osteopontin/ITG pathway (see, for example, NPL 7). In the results of the present example as well, molecule activation patterns were determined to be broadly classified into three patterns when KMG4 cells are seeded on DN gel (see
FIG. 12 ). These consist of (i) activation is increased in proportion of the cells depending on the time adhered on the DN gel (pFAK), (ii) activation begins soon after seeding on DN gel and remains activated (pAKT, p-p38MAPK), and (iii) activation consists of two peaks occurring at 6 hours and 48 hours after seeding the cells on DN gel (p-c-Met, pEGFR, pSrc, pERK). When Yap1, an important factor of the Hippo pathway, is knocked down by the siRNA method (knock-down efficiency: 80%), expression of each of Oct3/4, Sox2 and Nanog was determined to increase, while expression of stem cell marker molecules downstream from the Hippo pathway was determined to be suppressed in brain tumor cells. - Analysis of Tumor-forming Ability of Cancer Stem Cells Induced on DN Gel In Vivo in Mice
- The following experiment was carried out in order to analyze the tumor-forming ability of cancer stem cells induced on DN gel in vivo in mice. The experiment method is as indicated below.
-
- 1. Stable gene introduction of tdTomato-Luc2 in KMG4 cells
- 2. Case of culturing tdTomato-Luc2-introduced KMG4 cells for 3 days on DN gel (
group 1 below) - 3. Transplantation of 500 cells into the brains of immunosuppressed mice (NOD/Shijic-scid Jcl)
- The mice were divided into the following four groups: 1) mixed inoculation of KMG4 cells cultured for 3 days on DN gel with crushed DN gel (diameter: 100 pm or less); 2) inoculation of cells after culturing for 3 days on DN gel; 3) inoculation of cells after culturing for 3 days on PS dish; and 4) inoculation of crushed DN gel only. 500 cells were inoculated in each group. The results are shown in
FIG. 13 andFIG. 14 . Prominent tumor formation was observed in the system consisting of mixed inoculation of gels seeded on DN gel with crushed DN gel of group 1). This suggests that continuous stimulation from DN gel is required to induce stemness. - Analysis of Induction of Expression of Brain Tumor Stem Cell Markers on Synthetic Polymer Gels other than DN Gel
- Human brain tumor cell line (KMG4) cells were seeded at 1×105/mL on three types of synthetic polymer gels (DN, PCDME, PNaSS).
FIG. 15 indicates photographs of cells cultured for 3 days. Moreover, the results of confirming induction of expression of stem cell marker molecules (Sox2, Nanog, Oct3/4 mRNAs) by qRT-PCR are shown inFIG. 16 . In addition, the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR are shown inFIG. 19 . Cells cultured on an ordinary polystyrene culture dish (PS dish) were used as a negative control. Expression of stem cell marker molecules (Oct3/4, Sox2, Nanog mRNAs) and osteopontin (OPN mRNA) was confirmed to be induced in KMG4 cells cultured on PCDME and PNaSS gels. As shown inFIG. 15 , cells seeded on DN gel formed spheres and the cells adhered to and extended from the PCDME and PNaSS gels. - An analysis was carried out as to whether or not cancer stem cells induced on PCDME and PNaSS gels have the ability to form tumors in vivo in mice (
FIG. 17 ). 500 KMG4-luc cells cultured for 3 days on PCDME and PNaSS gels were inoculated into the brains of NOD/ShinJic-scid mice followed by observing tumor formation and growth over time using an IVIS system. Tumor formation was observed at three weeks after injection in all mice injected KMG4 cells cultured on PNaSS gel, and all of the mice died of cancer at seven weeks after inoculation. KMG4 cells inoculated on PCDME gel formed prominent tumors roughly one week later than in the case of PNaSS gel. Tumor-forming ability induced by both gels increased more prominently than that induced by DN gel. On the basis of these results, although continuous stimulation from DN gel was required for DN gel to induce cancer stem cells (group 3 above), PNaSS and PCDME gels were suggested to have the potential to be able to irreversibly induce conversion of cancer cells to cancer stem cells both alone and in a short period of time. - Conversion of Primary Cultured Cells Derived from Cancer Patients to Stem Cells by Polymer Gel
- A study was conducted as to whether or not polymer gel induces conversion of cells derived from actual patients to cancer stem cells and suggests a therapeutic target. Although G144 cells derived from patients with malignant brain tumors express EGF receptors under ordinary culture conditions, expression of PDGF receptors is observed only to the degree of being expressed in several cells. Induction of expression of PDGF receptors was observed in G144 cells in which sphere formation was induced by polymer gel (
FIG. 18 ). The growth of stem cells induced by polymer gel was suppressed by anti-PDGFR antibody in a treatment study. The above results suggest that polymer gel makes it possible to diagnosis stem cell profiles following relapse for samples obtained from cancer patients prior to treatment. - Analyses were further carried out using four types of synthetic polymer gels (PA, PAMPS, PDMA, PAAc). Human brain tumor cell line (KMG4) cells were seeded at 1×105 cells/mL on synthetic polymer gels consisting of PA, PAMPS, PDMA and PAAc and cultured for 3 days, and the results of confirming induction of expression of osteopontin (OPN) mRNA by qRT-PCR are shown in
FIG. 20 , while the results of confirming stem cell marker molecules (Oct3/4 and Nanog mRNAs) by qRT-PCR are shown inFIG. 21 . Cells cultured on an ordinary polystyrene dish (PS dish) were used as a negative control.FIG. 20 andFIG. 21 also indicate the expression analysis results for each of DN, PCDME and PNaSS gels for comparison. Induction of expression of stem cell marker molecules (Oct3/4 and Nanog mRNAs) and osteopontin (OPN) mRNA was confirmed in KMG4 cells cultured on PA, PAMPS, PDMA and PAAc gels in addition to that on DN, PCDME and PNaSS gels. As shown inFIG. 22 , KMG4 cells seeded on PA, PAMPS and PDMA gels and then cultured for 3 days formed spheres. Although KMG4 cells seeded and cultured in the same manner on PAAc gel adhered loosely to the gel, extension on the gel was not observed (adhesive, non-extending).FIG. 22 also indicates photographs of KMG4 cells seeded on DN, PCDME, and PNaSS gels and cultured for 3 days (DN: sphere formation, PCDME and PNaSS: adhesion and extension). - The present invention is useful in tumor-related fields in which stem cells are involved.
Claims (14)
1-11. (canceled)
12. An agent for inducing conversion of cancer cells from brain, lung or ovarian cancer tissue to cancer stem cells, containing a gel substance that is a synthetic polymer gel that induces expression of osteopontin in cells present in a living cell population obtained from cancer tissue, and converts at least a portion of cells contained in the living cell population into cancer stem cells; and said synthetic polymer gel is composed of poly(sodium p-styrene sulfonate) (PNaSS) gel, poly-N-(carboxymethyl-N,N-dimethyl-2-(methacryloyloxy) ethanaminium (PCDME) gel, polyampholyte (PA) gel, poly(2-acrylamido-2 methyl-1-propanesulfonic acid) (PAMPS) gel, poly (N,N′-dimethylacrylamide) (PDMA) gel, poly(acrylic acid) (PAAc) gel, or double network gel having an interpenetrating network structure of PAMPS gel and PDMA gel.
13. (canceled)
14. The agent for inducing conversion according to claim 12 , wherein the gel substance is in the form of a sheet or particles.
15-17. (canceled)
18. The agent for inducing conversion according to claim 12 , wherein the initial elastic modulus of the synthetic polymer is 0.0026 MPa or more and 0.435 MPa or less.
19. The agent for inducing conversion according to claim 12 , wherein the synthetic polymer induces a 2- to 13-fold higher level of osteopontin expression in the living cell population obtained from cancer tissue, compared with the polystyrene culture dish.
20. A method of testing an effect of a test substance on cancer stem cells from brain, lung or ovarian cancer tissue, comprising:
culturing a living cell population from said cancer tissue and/or said cancer stem cells in the presence of a test substance and the agent for inducing conversion defined in claim 12 .
21. The method according to claim 20 , wherein the living cell population containing cancer stem cells contains cells exhibiting a spherical structure.
22. The method according to claim 20 , wherein cells in the living cell population containing cancer stem cells have a higher expression level of Oct3/4, Sox2 and/or Nanog than that prior to culturing in the presence of the gel substance.
23. The method according to claim 20 , wherein the culturing is carried out in vitro.
24. The method according to claim 20 , wherein the living cell population containing cancer stem cells is a living cell population obtained by culturing a living cell population containing cancer cells in the presence of the gel substance.
25. The method according to claim 20 further comprising transplanting the cancer stem cell into mice.
26. The method according to claim 20 , wherein the double network gel is in the form of a sheet or particles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/480,956 US20240026286A1 (en) | 2017-02-20 | 2023-10-04 | Method of producing cancer stem cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017028833 | 2017-02-20 | ||
JP2017-028833 | 2017-02-20 | ||
PCT/JP2018/005884 WO2018151309A1 (en) | 2017-02-20 | 2018-02-20 | Method for producing cancer stem cells |
US201916487247A | 2019-12-06 | 2019-12-06 | |
US18/480,956 US20240026286A1 (en) | 2017-02-20 | 2023-10-04 | Method of producing cancer stem cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201916487247A Division | 2017-02-20 | 2019-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240026286A1 true US20240026286A1 (en) | 2024-01-25 |
Family
ID=63169728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/487,247 Active 2040-12-17 US11834671B2 (en) | 2017-02-20 | 2018-02-20 | Method of producing cancer stem cells |
US18/480,956 Pending US20240026286A1 (en) | 2017-02-20 | 2023-10-04 | Method of producing cancer stem cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/487,247 Active 2040-12-17 US11834671B2 (en) | 2017-02-20 | 2018-02-20 | Method of producing cancer stem cells |
Country Status (3)
Country | Link |
---|---|
US (2) | US11834671B2 (en) |
JP (1) | JP7115749B2 (en) |
WO (1) | WO2018151309A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023043525A (en) * | 2021-09-16 | 2023-03-29 | 国立大学法人北海道大学 | Cell culture vessel, cell culture kit, and cell culture method |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297290B2 (en) * | 2003-08-08 | 2007-11-20 | The Board Of Regents Of The University And Community College System Of Nevada | Nanostructured magnetorheological fluids and gels |
JP2010158180A (en) | 2009-01-06 | 2010-07-22 | Hokkaido Univ | Scaffold material |
JP5544719B2 (en) | 2009-01-27 | 2014-07-09 | 三菱レイヨン株式会社 | Gel and method for producing the same |
KR101364704B1 (en) * | 2012-06-12 | 2014-02-20 | 순천향대학교 산학협력단 | Method of porous hydrogel scaffold for osteanagenesis |
SG11201510462QA (en) | 2013-06-18 | 2016-01-28 | Agency Science Tech & Res | Method of culturing cancer stem cells |
US10227566B2 (en) * | 2013-10-30 | 2019-03-12 | University Of South Carolina | Three dimensional matrix for cancer stem cells |
JP2016083276A (en) | 2014-10-28 | 2016-05-19 | 国立大学法人北海道大学 | Intraoral appliance and method for manufacturing intraoral appliance |
-
2018
- 2018-02-20 JP JP2018568662A patent/JP7115749B2/en active Active
- 2018-02-20 WO PCT/JP2018/005884 patent/WO2018151309A1/en active Application Filing
- 2018-02-20 US US16/487,247 patent/US11834671B2/en active Active
-
2023
- 2023-10-04 US US18/480,956 patent/US20240026286A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7115749B2 (en) | 2022-08-09 |
WO2018151309A1 (en) | 2018-08-23 |
US11834671B2 (en) | 2023-12-05 |
JPWO2018151309A1 (en) | 2019-12-12 |
US20200095541A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240026286A1 (en) | Method of producing cancer stem cells | |
EP2138571B1 (en) | Process for the preparation of multicellular spheroids | |
US11441120B2 (en) | Cell culture substrate | |
CN101824123B (en) | High-strength temperature-sensitive hydrogel as well as preparation method and application thereof | |
Han et al. | Chitosan-hyaluronan based 3D co-culture platform for studying the crosstalk of lung cancer cells and mesenchymal stem cells | |
De Luca et al. | Positively charged polymers modulate the fate of human mesenchymal stromal cells via ephrinB2/EphB4 signaling | |
Zhao et al. | Inhibition of protein adsorption and cell adhesion on PNIPAAm-grafted polyurethane surface: Effect of graft molecular weight | |
JP6375358B2 (en) | Cell culture composition and cell culture vessel | |
Mizumoto et al. | Expression of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis | |
Rezaeeyazdi et al. | Engineering hyaluronic acid-based cryogels for CD44-mediated breast tumor reconstruction | |
Spelat et al. | A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells | |
Zhou et al. | Expansion of ovarian cancer stem-like cells in poly (ethylene glycol)-cross-linked poly (methyl vinyl ether-alt-maleic acid) and alginate double-network hydrogels | |
Lin et al. | Viscoelastic hydrogels for interrogating pancreatic cancer-stromal cell interactions | |
Wang et al. | Circular Patterns of Dynamic Covalent Hydrogels with Gradient Stiffness for Screening of the Stem Cell Microenvironment | |
JP2010035528A (en) | Culture medium material and gene introduction method | |
CN106237336B (en) | A kind of breast cancer combined chemotherapy nano combined graphene aquogel system and preparation method thereof | |
CN110628699B (en) | Preparation method of lung hardness substrate in-vitro cell culture platform | |
JP6286947B2 (en) | Cell aggregate production method and drug screening method | |
JPWO2020153364A1 (en) | Cell adhesion sheet | |
JP7018175B2 (en) | Copolymers, surface treatment agents for substrates and cell culture substrates | |
WO2020076807A1 (en) | Cell culture surface compositions, systems, and methods | |
JP6183070B2 (en) | Cell aggregate production method and drug screening method | |
CN110699322B (en) | Three-dimensional tumor cell culture medium and preparation method thereof | |
WO2017110923A1 (en) | Resin composition, substrate, and cell culture method | |
Wouters et al. | POLARIZATION OF HUMAN MACROPHAGES INTO M1 AND M2 PHENOTYPES IS STIFFNESS INDEPENDENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |